20(S)-protopanaxadiol, an active ginseng metabolite, exhibits strong antidepressant-like effects in animal tests

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 34, Issue 8, 2010, Pages 1402-1411

  Xu, Changjiang ^a   Teng, Jijun ^a   Chen, Weidong ^a   Ge, Qiang ^a   Yang, Zhiqi ^a   Yu, Chunying ^a   Yang, Zirong ^a   Jia, William ^a,b  

^a Department of Rehabilitation Medicine   (China)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Depression; Ginseng; Ginsenosides; PMC; Post metabolism compound

Indexed keywords

CORTICOSTERONE; ESTAZOLAM; FLUOXETINE; MALONALDEHYDE; MONOAMINE; NEUROTRANSMITTER; PROTOPANAXADIOL; S 111; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DEPRESSION; DOWN REGULATION; DRUG ACTIVITY; DRUG POTENCY; FORCED SWIMMING TEST; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; OLFACTORY BULBECTOMY; OXIDATIVE STRESS; PASSIVE AVOIDANCE; RAT;

EID: 78649508751     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2010.07.010     Document Type: Article

References (101)

1. Archer T., Soderberg U., Ross S.B., Jonsson G. Role of olfactory bulbectomy and DSP4 treatment in avoidance learning in the rat. Behav Neurosci 1984, 98(3):496-505.
2. Bae E.A., Hyun Y.J., Choo M.K., Oh J.K., Ryu J.H., Kim D.H. Protective effect of fermented red ginseng on a transient focal ischemic rats. Arch Pharm Res 2004, 27(11):1136-1140.
3. Becker C., Zeau B., Rivat C., Blugeot A., Hamon M., Benoliel J.J. Repeated social defeat-induced depression-like behavioral and biological alterations in rats: involvement of cholecystokinin. Mol Psychiatry 2008, 13(12):1079-1092.
4. Berton O., Nestler E.J. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 2006, 7(2):137-151.
5. Bhattcharyya D., Sur T.K. Effect of Panax ginseng and diazepam on brain 5-hydroxytryptamine and its modification by diclofenac in rat. Indian J Physiol Pharmacol 1999, 43(4):505-509.
6. Bilici M., Efe H., Koroglu M.A., Uydu H.A., Bekaroglu M., Deger O. Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. J Affect Disord 2001, 64(1):43-51.
7. Block M.L. NADPH oxidase as a therapeutic target in Alzheimer's disease. BMC Neurosci 2008, 9(Suppl 2):S8.
8. Brunoni A.R., Lopes M., Fregni F. A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int J Neuropsychopharmacol 2008, 11(8):1169-1180.
9. Carroll B.J., Curtis G.C., Davies B.M., Mendels J., Sugerman A.A. Urinary free cortisol excretion in depression. Psychol Med 1976, 6(1):43-50.
10. Chang H.F., Lin Y.H., Chu C.C., Wu S.J., Tsai Y.H., Chao J.C. Protective effects of Ginkgo biloba, Panax ginseng, and Schizandra chinensis extract on liver injury in rats. Am J Chin Med 2007, 35(6):995-1009.
11. Chen Z., Skolnick P. Triple uptake inhibitors: therapeutic potential in depression and beyond. Expert Opin Investig Drugs 2007, 16(9):1365-1377.
12. Cheng X.J., Liu Y.L., Deng Y.S., Lin G.F., Luo X.T. Effects of ginseng root saponins on central transmitters and plasma corticosterone in cold stress mice and rats. Zhongguo Yao Li Xue Bao 1987, 8(6):486-489.
13. Chu S.F., Zhang J.T. New achievements in ginseng research and its future prospects. Chin J Integr Med 2009, 15(6):403-408.
14. Curzon G., Green A.R. Rapid method for the determination of 5-hydroxytryptamine and 5-hydroxyindoleacetic acid in small regions of rat brain. Br J Pharmacol 1970, 39(3):653-655.
15. Dang H., Chen Y., Liu X., Wang Q., Wang L., Jia W., et al. Antidepressant effects of ginseng total saponins in the forced swimming test and chronic mild stress models of depression. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33(8):1417-1424.
16. Dannlowski U., Ohrmann P., Konrad C., Domschke K., Bauer J., Kugel H., et al. Reduced amygdala-prefrontal coupling in major depression: association with MAOA genotype and illness severity. Int J Neuropsychopharmacol 2009, 12(1):11-22.
17. Deng H.L., Zhang J.T. Anti-lipid peroxilative effect of ginsenoside Rb1 and Rg1. Chin Med J (Engl) 1991, 104(5):395-398.
18. Dolphin A., Elliott P.N., Jenner P. The irritant properties of dopamine-beta-hydroxylase inhibitors in relation to their effects on l-Dopa-induced locomotor activity. J Pharm Pharmacol 1976, 28(10):782-785.
19. Duman R.S. Synaptic plasticity and mood disorders. Mol Psychiatry 2002, 7(Suppl 1):S29-S34.
20. Ernst E. Review: St John's wort superior to placebo and similar to antidepressants for major depression but with fewer side effects. Evid Based Ment Health 2009, 12(3):78.
21. Feng, L. M., Pan, H. Z., Li, W. W. Anti-oxidant action of Panax ginseng. Zhong Xi Yi Jie He Za Zhi 1987;7(5):288-90, 262.
22. Frodl T., Jager M., Smajstrlova I., Born C., Bottlender R., Palladino T., et al. Effect of hippocampal and amygdala volumes on clinical outcomes in major depression: a 3-year prospective magnetic resonance imaging study. J Psychiatry Neurosci 2008, 33(5):423-430.
23. Fuchs E., Fliugge G. Experimental animal models for the simulation of depression and anxiety. Dialogues Clin Neurosci 2006, 8(3):323-333.
24. Gronan R.J. Time and dose influences on the behavioral effects of l-Dopa and 5-hydroxytryptophan after inhibition of extracerebral decarboxylase. Pharmacol Biochem Behav 1975, 3(2):161-166.
25. Grunze H.C. Switching, induction of rapid cycling, and increased suicidality with antidepressants in bipolar patients: fact or overinterpretation?. CNS Spectr 2008, 13(9):790-795.
26. Han M., Sha X., Wu Y., Fang X. Oral absorption of ginsenoside Rb1 using in vitro and in vivo models. Planta Med 2006, 72(5):398-404.
27. Hasegawa H., Sung J.H., Matsumiya S., Uchiyama M. Main ginseng saponin metabolites formed by intestinal bacteria. Planta Med 1996, 62(5):453-457.
28. Hasegawa H., Sung J.H., Benno Y. Role of human intestinal Prevotella oris in hydrolyzing ginseng saponins. Planta Med 1997, 63(5):436-440.
29. He W., Liu G., Chen X., Lu J., Abe H., Huang K., et al. Inhibitory effects of ginsenosides from the root of Panax ginseng on stimulus-induced superoxide generation, tyrosyl or serine/threonine phosphorylation, and translocation of cytosolic compounds to plasma membrane in human neutrophils. J Agric Food Chem 2008, 56(6):1921-1927.
30. Hendrie C.A., Pickles A.R., Duxon M.S., Riley G., Hagan J.J. Effects of fluoxetine on social behaviour and plasma corticosteroid levels in female Mongolian gerbils. Behav Pharmacol 2003, 14(7):545-550.
31. Hiai S., Yokoyama H., Oura H., Yano S. Stimulation of pituitary-adrenocortical system by ginseng saponin. Endocrinol Jpn 1979, 26(6):661-665.
32. Huong N.T., Matsumoto K., Kasai R., Yamasaki K., Watanabe H. In vitro antioxidant activity of Vietnamese ginseng saponin and its components. Biol Pharm Bull 1998, 21(9):978-981.
33. Ichikawa H., Wang L., Konishi T. Prevention of cerebral oxidative injury by post-ischemic intravenous administration of Shengmai San. Am J Chin Med 2006, 34(4):591-600.
34. Jacobowitz D.M., Richardson J.S. Method for the rapid determination of norepinephrine, dopamine, and serotonin in the same brain region. Pharmacol Biochem Behav 1978, 8(5):515-519.
35. Kennedy D.O., Scholey A.B. Ginseng: potential for the enhancement of cognitive performance and mood. Pharmacol Biochem Behav 2003, 75(3):687-700.
36. Kim C., Kim C.C., Kim M.S., Hu C.Y., Rhe J.S. Influence of ginseng on the stress mechanism. Lloydia 1970, 33(1):43-48.
37. Kim D.H., Jung J.S., Suh H.W., Huh S.O., Min S.K., Son B.K., et al. Inhibition of stress-induced plasma corticosterone levels by ginsenosides in mice: involvement of nitric oxide. Neuroreport 1998, 9(10):2261-2264.
38. Kim S.R., Sung S.H., Kwon S.W., Park J.H., Huh H., Kim Y.C. Dammarane derivatives protect cultured rat cortical cells from glutamate-induced neurotoxicity. J Pharm Pharmacol 2000, 52(12):1505-1511.
39. Kim D.H., Jung J.S., Moon Y.S., Sung J.H., Suh H.W., Kim Y.H., et al. Inhibition of intracerebroventricular injection stress-induced plasma corticosterone levels by intracerebroventricularly administered compound K, a ginseng saponin metabolite, in mice. Biol Pharm Bull 2003, 26(7):1035-1038.
40. Kim D.H., Moon Y.S., Jung J.S., Min S.K., Son B.K., Suh H.W., et al. Effects of ginseng saponin administered intraperitoneally on the hypothalamo-pituitary-adrenal axis in mice. Neurosci Lett 2003, 343(1):62-66.
41. Kim Y.O., Kim H.J., Kim G.S., Park H.G., Lim S.J., Seong N.S., et al. Panax ginseng protects against global ischemia injury in rat hippocampus. J Med Food 2009, 12(1):71-76.
42. Kronenberg G., Tebartz van Elst L., Regen F., Deuschle M., Heuser I., Colla M. Reduced amygdala volume in newly admitted psychiatric in-patients with unipolar major depression. J Psychiatr Res 2009.
43. Lanni C., Govoni S., Lucchelli A., Boselli C. Depression and antidepressants: molecular and cellular aspects. Cell Mol Life Sci 2009, 66(18):2985-3008.
44. Lee B.M., Lee S.K., Kim H.S. Inhibition of oxidative DNA damage, 8-OHdG, and carbonyl contents in smokers treated with antioxidants (vitamin E, vitamin C, beta-carotene and red ginseng). Cancer Lett 1998, 132(1-2):219-227.
45. Lee S.H., Jung B.H., Kim S.Y., Lee E.H., Chung B.C. The antistress effect of ginseng total saponin and ginsenoside Rg3 and Rb1 evaluated by brain polyamine level under immobilization stress. Pharmacol Res 2006, 54(1):46-49.
46. Leonard B.E. The olfactory bulbectomized rat as a model of depression. Pol J Pharmacol Pharm 1984, 36(5):561-569.
47. Li J., Huang M., Teoh H., Man R.Y. Panax quinquefolium saponins protects low density lipoproteins from oxidation. Life Sci 1999, 64(1):53-62.
48. Lian X.Y., Zhang Z., Stringer J.L. Protective effects of ginseng components in a rodent model of neurodegeneration. Ann Neurol 2005, 57(5):642-648.
49. Liao B., Newmark H., Zhou R. Neuroprotective effects of ginseng total saponin and ginsenosides Rb1 and Rg1 on spinal cord neurons in vitro. Exp Neurol 2002, 173(2):224-234.
50. Lim J.H., Wen T.C., Matsuda S., Tanaka J., Maeda N., Peng H., et al. Protection of ischemic hippocampal neurons by ginsenoside Rb1, a main ingredient of ginseng root. Neurosci Res 1997, 28(3):191-200.
51. Lin E., Wang Y., Mehendale S., Sun S., Wang C.Z., Xie J.T., et al. Antioxidant protection by American ginseng in pancreatic beta-cells. Am J Chin Med 2008, 36(5):981-988.
52. Lopez M.V., Cuadrado M.P., Ruiz-Poveda O.M., Del Fresno A.M., Accame M.E. Neuroprotective effect of individual ginsenosides on astrocytes primary culture. Biochim Biophys Acta 2007, 1770(9):1308-1316.
53. Lopez-Munoz F., Alamo C. Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today. Curr Pharm Des 2009, 15(14):1563-1586.
54. Lucki I., Dalvi A., Mayorga A.J. Sensitivity to the effects of pharmacologically selective antidepressants in different strains of mice. Psychopharmacology (Berl) 2001, 155(3):315-322.
55. Maj J., Pawlowski The effect of L-5-hydroxytryptophan (5-HTP) on locomotor activity in mice. Pol J Pharmacol Pharm 1975, 27(Suppl):145-149.
56. Marcilhac A., Faudon M., Anglade G., Hery F., Siaud P. An investigation of serotonergic involvement in the regulation of ACTH and corticosterone in the olfactory bulbectomized rat. Pharmacol Biochem Behav 1999, 63(4):599-605.
57. McArthur R., Borsini F. Animal models of depression in drug discovery: a historical perspective. Pharmacol Biochem Behav 2006, 84(3):436-452.
58. McDaniel J.S., Musselman D.L., Porter M.R., Reed D.A., Nemeroff C.B. Depression in patients with cancer. Diagnosis, biology, and treatment. Arch Gen Psychiatry 1995, 52(2):89-99.
59. Miura H., Ozaki N., Sawada M., Isobe K., Ohta T., Nagatsu T. A link between stress and depression: shifts in the balance between the kynurenine and serotonin pathways of tryptophan metabolism and the etiology and pathophysiology of depression. Stress 2008, 11(3):198-209.
60. Nakamura T., Lipton S.A. Cell death: protein misfolding and neurodegenerative diseases. Apoptosis 2009, 14(4):455-468.
61. Naval M.V., Gomez-Serranillos M.P., Carretero M.E., Villar A.M. Neuroprotective effect of a ginseng (Panax ginseng) root extract on astrocytes primary culture. J Ethnopharmacol 2007, 112(2):262-270.
62. Ozcan M.E., Gulec M., Ozerol E., Polat R., Akyol O. Antioxidant enzyme activities and oxidative stress in affective disorders. Int Clin Psychopharmacol 2004, 19(2):89-95.
63. Papakostas G.I. The efficacy, tolerability, and safety of contemporary antidepressants. J Clin Psychiatry 2010, 71(Suppl E1):e03.
64. Paparrigopoulos T., Ferentinos P., Brierley B., Shaw P., David A.S. Relationship between post-operative depression/anxiety and hippocampal/amygdala volumes in temporal lobectomy for epilepsy. Epilepsy Res 2008, 81(1):30-35.
65. Pariante C.M., Lightman S.L. The HPA axis in major depression: classical theories and new developments. Trends Neurosci 2008, 31(9):464-468.
66. Park J.K., Namgung U., Lee C.J., Park J.O., Jin S.H., Kwon O.B., et al. Calcium-independent CaMKII activity is involved in ginsenoside Rb1-mediated neuronal recovery after hypoxic damage. Life Sci 2005, 76(9):1013-1025.
67. Peet M., Murphy B., Shay J., Horrobin D. Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients. Biol Psychiatry 1998, 43(5):315-319.
68. Porsolt R.D., Bertin A., Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 1977, 229(2):327-336.
69. Qian T., Jiang Z.H., Cai Z. High-performance liquid chromatography coupled with tandem mass spectrometry applied for metabolic study of ginsenoside Rb1 on rat. Anal Biochem 2006, 352(1):87-96.
70. Radad K., Gille G., Moldzio R., Saito H., Rausch W.D. Ginsenosides Rb1 and Rg1 effects on mesencephalic dopaminergic cells stressed with glutamate. Brain Res 2004, 1021(1):41-53.
71. Rai D., Bhatia G., Sen T., Palit G. Anti-stress effects of Ginkgo biloba and Panax ginseng: a comparative study. J Pharmacol Sci 2003, 93(4):458-464.
72. Redmond A.M., Kelly J.P., Leonard B.E. The determination of the optimal dose of milnacipran in the olfactory bulbectomized rat model of depression. Pharmacol Biochem Behav 1999, 62(4):619-623.
73. Salisbury A.L., Ponder K.L., Padbury J.F., Lester B.M. Fetal effects of psychoactive drugs. Clin Perinatol 2009, 36(3):595-619.
74. Sampson D., Willner P., Muscat R. Reversal of antidepressant action by dopamine antagonists in an animal model of depression. Psychopharmacology (Berl) 1991, 104(4):491-495.
75. Samukawa K., Suzuki Y., Ohkubo N., Aoto M., Sakanaka M., Mitsuda N. Protective effect of ginsenosides Rg(2) and Rh(1) on oxidation-induced impairment of erythrocyte membrane properties. Biorheology 2008, 45(6):689-700.
76. Schweitzer I., Maguire K., Ng C. Sexual side-effects of contemporary antidepressants: review. Aust N Z J Psychiatry 2009, 43(9):795-808.
77. Selye H. Stress and disease. Trans Am Laryngol Rhinol Otol Soc 1955, 312-326. discussion, 326-9.
78. Shah Z.A., Gilani R.A., Sharma P., Vohora S.B. Cerebroprotective effect of Korean ginseng tea against global and focal models of ischemia in rats. J Ethnopharmacol 2005, 101(1-3):299-307.
79. Sheline Y.I. Neuroimaging studies of mood disorder effects on the brain. Biol Psychiatry 2003, 54(3):338-352.
80. Shen L., Han J.Z., Li C., Yue S.J., Liu Y., Qin X.Q., et al. Protective effect of ginsenoside Rg1 on glutamate-induced lung injury. Acta Pharmacol Sin 2007, 28(3):392-397.
81. Shirayama Y., Chen A.C., Nakagawa S., Russell D.S., Duman R.S. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci 2002, 22(8):3251-3261.
82. Singh A., Garg V., Gupta S., Kulkarni S.K. Role of antioxidants in chronic fatigue syndrome in mice. Indian J Exp Biol 2002, 40(11):1240-1244.
83. Song C., Leonard B.E. The olfactory bulbectomised rat as a model of depression. Neurosci Biobehav Rev 2005, 29(4-5):627-647.
84. Steru L., Chermat R., Thierry B., Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl) 1985, 85(3):367-370.
85. Sulser F., Brodie B.B. The mechanism of action of a new type of antidepressant drug which does not block monoamine oxidase. Chic Med 1962, 65:9-11.
86. Swaab D.F., Bao A.M., Lucassen P.J. The stress system in the human brain in depression and neurodegeneration. Ageing Res Rev 2005, 4(2):141-194.
87. Takahashi M., Tokuyama S., Kaneto H. Anti-stress effect of ginseng on the inhibition of the development of morphine tolerance in stressed mice. Jpn J Pharmacol 1992, 59(3):399-404.
88. Tawab M.A., Bahr U., Karas M., Wurglics M., Schubert-Zsilavecz M. Degradation of ginsenosides in humans after oral administration. Drug Metab Dispos 2003, 31(8):1065-1071.
89. Thomas D.R., Nelson D.R., Johnson A.M. Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor. Psychopharmacology (Berl) 1987, 93(2):193-200.
90. Tode T., Kikuchi Y., Hirata J., Kita T., Nakata H., Nagata I. Effect of Korean red ginseng on psychological functions in patients with severe climacteric syndromes. Int J Gynaecol Obstet 1999, 67(3):169-174.
91. van Eijndhoven P., van Wingen G., van Oijen K., Rijpkema M., Goraj B., Jan Verkes R., et al. Amygdala volume marks the acute state in the early course of depression. Biol Psychiatry 2009, 65(9):812-818.
92. Depression, Vol. 2010 2010, WHO, World Health Organization.
93. Wiklund I.K., Mattsson L.A., Lindgren R., Limoni C. Effects of a standardized ginseng extract on quality of life and physiological parameters in symptomatic postmenopausal women: a double-blind, placebo-controlled trial. Swedish Alternative Medicine Group. Int J Clin Pharmacol Res 1999, 19(3):89-99.
94. Wu X., LIU J. Optimization of the conditions for measurement of monoamine neurotransmitters in rat brain by fluorescence. Acta Pharmacol Sin 1987, 3(6):371-374.
95. Yi L.T., Xu Q., Li Y.C., Yang L., Kong L.D. Antidepressant-like synergism of extracts from magnolia bark and ginger rhizome alone and in combination in mice. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33(4):616-624.
96. Yoshikawa T., Akiyoshi Y., Susumu T., Tokado H., Fukuzaki K., Nagata R., et al. Ginsenoside Rb1 reduces neurodegeneration in the peri-infarct area of a thromboembolic stroke model in non-human primates. J Pharmacol Sci 2008, 107(1):32-40.
97. Yuan W.X., Wu X.J., Yang F.X., Shang X.H., Zhang L.L. Effects of ginseng root saponins on brain monoamines and serum corticosterone in heat-stressed mice. Zhongguo Yao Li Xue Bao 1989, 10(6):492-496.
98. Yulug B., Ozan E., Gonul A.S., Kilic E. Brain-derived neurotrophic factor, stress and depression: a minireview. Brain Res Bull 2009, 78(6):267-269.
99. Zhang Y.G., Liu T.P. Influences of ginsenosides Rb1 and Rg1 on reversible focal brain ischemia in rats. Zhongguo Yao Li Xue Bao 1996, 17(1):44-48.
100. Zhang Y., Raap D.K., Garcia F., Serres F., Ma Q., Battaglia G., et al. Long-term fluoxetine produces behavioral anxiolytic effects without inhibiting neuroendocrine responses to conditioned stress in rats. Brain Res 2000, 855(1):58-66.
101. Zheng C.D., Min S. Cardioprotection of Shenfu Injection against myocardial ischemia/reperfusion injury in open heart surgery. Chin J Integr Med 2008, 14(1):10-16.